Total : 1 View more »
BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical.
Total : 23 View more »
Sep 26, 2009 (Wall Street Horizon via COMTEX) --
YM BioSciences Inc. (YMI)
Expected next earnings release: Announcement date: 11/11/2009 - Before Market Earnings Quarter: Q1 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: YM Biosciences Inc (YMI)
Oct 07, 2009 (Wall Street Horizon via COMTEX) --
YM BioSciences Inc. (YMI)
Expected next earnings release: Announcement date: 11/12/2009 - Before Market Earnings Quarter: Q1 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: YM Biosciences Inc (YMI)
Sep 25, 2009 (Wall Street Horizon via COMTEX) --
YM BioSciences Inc. (YMI)
Expected next earnings release: Announcement date: 9/25/2009 - Before Market Earnings Quarter: Q4 Announcement Status: Verified
Tags: corporate earnings market
Companies: YM Biosciences Inc (YMI)
Sep 04, 2009 (Wall Street Horizon via COMTEX) --
YM BioSciences Inc. (YMI)
Expected next earnings release: Announcement date: 9/17/2009 - After Market Earnings Quarter: Q4 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: YM Biosciences Inc (YMI)
Total : 5 View more »
BIO InvestorForum 2008 When: October 30, 2008 / 2:15pm PDT Where: Palace Hotel, Sea Cliff Room - San Francisco, CA Sean Thompson, VP Corporate Development, will be presenting at this conference. [listen to webcast]
The "YM" BioSciences might stand for "young and modern" as once the letters of YM magazine did. The firm was founded in 1994 to develop a variety of new anti-cancer technologies.
http://www.hoovers.com/ym-biosciences/--ID__119170--/freeuk-co-factsheet.xhtml
Description: The YM BioSciences Inc Financial Report contains the company’s contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues.
http://www.researchandmarkets.co.uk/reports/332460/ym_biosciences_inc_financial_report.pdf
YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator (for taxanes and anthracyclines) currently undergoing a pivotal Phase III trial in metastatic breast cancer.
Total : 31 View more »
YM BIOSCIENCES INCORPORATED (AMEX: YMI) "Up 67.85% on Tuesday" Detailed Quote: http://www.otcpicks.com/quotes/YMI.php . YM BioSciences Inc. is a life sciences product development ...
http://www.transworldnews.com/NewsStory.aspx?id=114342&cat=1
YM BIOSCIENCES INCORPORATED (AMEX: YMI) "Up 8.51% in morning trading" YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse ...
YM BIOSCIENCES INCORPORATED (AMEX: YMI) "Up 70.66% in morning trading" YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse ...
YM BIOSCIENCES INCORPORATED (AMEX: YMI | Quote | Chart | News | PowerRating) "Up 58.59% on Monday" Detailed Quote: http://www.otcpicks.com/quotes/YMI.php
http://www.tradingmarkets.com/.site/news/Stock%20News/2472238/